Human leukocyte antigen A*24:02 presenting URLC10, CDCA1, and KIF20A peptides (HLA-A*24:02/URLC10-CDCA1-KIF20A)

The target complex consisting of Human leukocyte antigen A*24:02 (HLA-A*24:02) presenting peptides from URLC10, CDCA1, and KIF20A is a focal point for cancer immunotherapy, particularly in East Asian populations where the HLA-A*24:02 allele is highly prevalent [1][2]. HLA-A*24:02 is a Major Histocompatibility Complex (MHC) class I molecule that presents intracellularly processed peptides to CD8+ cytotoxic T lymphocytes (CTLs) [2]. The three specific antigens—Up-regulated in lung cancer 10 (URLC10, also known as LY6K), Cell division cycle associated 1 (CDCA1, also known as NUF2), and Kinesin family member 20A (KIF20A)—are tumor-associated antigens (TAAs) that are significantly overexpressed in various malignancies, including pancreatic, esophageal, and lung cancers, while remaining minimally expressed in normal tissues [3][4][5]. Therapeutic interventions like the multi-peptide vaccine OCV-C01 target this complex to prime the immune system to recognize and destroy tumor cells [1][6]. By utilizing multiple epitopes, this approach aims to enhance the breadth of the immune response and reduce the likelihood of tumor escape [6][7]. Clinical studies have demonstrated that targeting this peptide-MHC complex can successfully induce antigen-specific CTL responses and may improve clinical outcomes in patients with advanced gastrointestinal and respiratory cancers [1][2][7]. Sources: [1] Suda et al. (2014) Cancer Sci 105(4):411-6; [2] Kono et al. (2012) Cancer Sci 103(6):1032-8; [3] Ishikawa et al. (2007) Cancer Res 67(24):11601-11; [4] Hayama et al. (2006) Cancer Res 66(21):10339-48; [5] Taniuchi et al. (2005) Cancer Res 65(1):105-12; [6] Yamaue et al. (2015) J Gastroenterol 50(2):226-39; [7] ClinicalTrials.gov NCT01223235.

Other names

OCV-C01 targetS-288310 targetHLA-A24-restricted multi-peptide vaccine targetLY6K/NUF2/KIF20A peptide-MHC complexHLA-A*24:02-restricted tumor-associated antigens

Peptide vaccine-mediated induction of antigen-specific cytotoxic T lymphocytes (CTLs) that recognize and eliminate tumor cells presenting these specific epitopes via the HLA-A*24:02 molecule.